Explore the Agenda
7:30 am Morning Breakfast & Registration
8:25 am Chair’s Opening Remarks
Late-Breaking Clinical Data: Analysing the Phase II–III Readouts Reshaping the Future of Radiopharmaceutical Oncology
8:30 am A Physician’s Perspective: Delivering RLTs at the Frontline of Patient Care & Witnessing Their Real-World Impact
- Sharing personal experiences from treating patients with radioligand therapies, including the moments that transformed perceptions of what targeted radiation can achieve in oncology care
- Reflecting on the emotional, clinical and human realities of guiding patients through RLT treatment journeys, from hope and uncertainty to long-term response and quality-of-life improvement
- Exploring why physicians delivering these therapies believe radiopharmaceuticals have the potential to reshape cancer treatment paradigms and what still needs to change to bring these benefits to more patients earlier in their disease journey
9:00 am Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development
- Presenting Phase II clinical data evaluating the safety, efficacy and therapeutic potential of Pb-212-based targeted alpha therapies
- Exploring how clinical findings are shaping patient selection, dosing strategies and future development decisions
- Examining the key translational and operational learnings generated throughout Phase II development
9:30 am Redefining PRRT: Advancing EBTATE Towards a New Standard of Care for Gastroenteropancreatic Neuroendocrine Tumours
- Presenting the latest clinical data supporting EBTATE, including encouraging efficacy, safety and durability outcomes as the programme advances towards pivotal Phase III evaluation
- Examining how enhanced tumour retention and albumin-binding technology enables meaningful therapeutic responses with substantially lower administered radioactivity and without amino acid co-infusion
- Comparing the clinical and practical implications of next-generation PRRT against existing treatment paradigms to understand where meaningful differentiation can be achieved
10:00 am Morning Break & Networking
Discovery & Preclinical Track
Discovery & Preclinical
From First-in-Class to Best-in-Class: Expanding Novel TRP Targets Beyond PSMA & SSTR to Unlock the Next Wave of Clinical Opportunity
11:00 am Advancing PSMA Radiopharmaceuticals into the Clinic: Lessons Learned from Navigating the CDE Approval Pathway
Chief Scientific Officer, Vitsgen Therapeutics, Inc.
- Sharing the development journey of a PSMA-targeted radiopharmaceutical from preclinical development through to Phase I clinical evaluation
- Exploring key considerations when preparing regulatory submissions to the Chinese CDE and identifying opportunities to accelerate clinical entry
- Understanding the similarities and differences between CDE and FDA expectations for radiopharmaceutical development
- Highlighting practical lessons learned from generating the data package required to support successful first-in-human studies and future global development
11:30 am Reimagining Antibody-Based Radiopharmaceuticals: Using Click-to-Release Technology to Expand the Therapeutic Window Across Multiple Targets
Chief Scientific Officer & Founder, Tagworks Pharmaceuticals BV
- Leveraging preclinical imaging, dosimetry and translational data to demonstrate how click-to-release technology can selectively remove circulating radioactivity whilst preserving tumour-bound activity
- Exploring how established ADC targets and internalisation pathways can be leveraged to accelerate the development of next-generation radiopharmaceutical programmes
- Examining the potential to overcome historical blood and kidney dose limitations associated with antibody-based radiopharmaceuticals and unlock a broader range of therapeutic targets
12:00 pm Moving Beyond Cell Surface Receptors: Advancing First-in-Class Tumour Microenvironment Targets into the Clinic
Chief Executive Officer, Lumina Pharmaceuticals
- Presenting the rationale for targeting the tumour microenvironment as a next-generation approach to radiopharmaceutical development
- Exploring the potential advantages of non-cell receptorbased targeting strategies in expanding patient eligibility and improving therapeutic flexibility
- Sharing lessons learned from advancing a first-in-class radiopharmaceutical programme through Phase 0 clinical evaluation
Translational & Clinical Track
Supply Chain & CMC
12:30 pm Lunch Break
Discovery & Preclinical Track
Expanding TRPs into New Disease Indications: Matching the Right Targets, Isotopes & Delivery Strategies to Emerging Cancer Opportunities
1:30 pm Beyond Peptides: Advancing Radio-DARPin Therapeutics from Platform Innovation to Clinical Proof-of- Concept
Chief Scientific Officer, Molecular Partners
- Presenting imaging and dosimetry insights from MP0712, a DLL3-targeted Pb-212 Radio-DARPin Therapeutic currently in Phase I development
- Exploring how half-life extended Radio-DARPins are designed to overcome the limitations of conventional peptide-based radiopharmaceutical approaches for challenging targets
- Sharing key learnings from advancing a novel targeted alpha therapy approach across clinical and preclinical development programmes
2:00 pm Expanding Radiopharmaceuticals Beyond Established Indications Through Engineered Scaffold Proteins
Chief Scientific Officer, Affibody AB
- Leveraging Affibody molecules to target HER2, HER3, B7-H3 and other emerging oncology targets
- Expanding RLTs into breast, gastric, ovarian, lung and other solid tumours through improved tumour penetration
- Selecting the optimal targeting scaffold for challenging tumour biology
- Translating novel targets into clinically viable radiopharmaceutical programmes
2:30 pm Advancing CAIX-Targeted Radiopharmaceuticals: Developing Next-Generation Precision Diagnostics for Clear Cell Renal Cell Carcinoma
Chief Technology Officer, Norroy Bioscience CO., LTD
- Evaluating the clinical rationale for targeting CAIX to improve the detection and characterisation of clear cell renal cell carcinoma
- Optimising small molecule radiopharmaceutical design to enable same-day imaging and improved detection of primary and metastatic disease
- Generating early clinical evidence through investigator-initiated studies to validate target engagement, imaging performance and clinical translation
Translational & Clinical Track
Supply Chain & CMC
3:00 pm Afternoon Break & Networking
Translating TRP Innovation into Commercial Reality: Lessons for Scaling Access, Infrastructure & Market Adoption
3:30 pm From Spot Supply to Strategic Control: What Bicycle’s ²¹²Pb Infrastructure Strategy Signals for the Future of TRP Supply Security
- Assessing the therapeutic potential of Lead-212 and the clinical rationale supporting its continued development
- Exploring the logistical and supply challenges associated with short half-life isotopes and how developers can successfully navigate them
- Understanding the balance between operational complexity and potential clinical advantages when selecting radionuclides
4:00 pm From Scientific Promise to Commercial Reality: How Should the Industry Prioritise the Next Generation of Radioligand Therapy Opportunities?
- Evaluating which targets, indications and development strategies are most likely to translate into clinically impactful and commercially successful radioligand therapies
- Understanding how leading organisations assess emerging opportunities and differentiate between promising innovation and crowded market segments
- Exploring how competitive intelligence, early clinical data and evolving market dynamics can be leveraged to inform portfolio and investment decisions
4:30 pm Future Directions Panel Discussion: One Final Question: What Must the TRP Community Solve Before We Meet Again?
- Identifying the single highest-priority challenge that must be solved to accelerate the next generation of radiopharmaceutical development
- Aligning scientific, clinical, regulatory and commercial perspectives to define the industry’s most critical priorities for the year ahead
- Shaping a shared roadmap for the innovations, collaborations and breakthroughs needed before reconvening at the 9th Targeted Radiopharmaceuticals Summit Europe